Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

The state agency warns that the snails were found to have a "low-level presence" of rat lungworm. They note that likelihood ...

BulletinHealthcare, a leading provider of news briefings for healthcare providers, announced today the launch of its latest publication, Respiratory Report: Pulmonary and Critical Care News Briefing, ...

The aim of this study was to characterise neutrophil subsets in bronchial lavage (BL) of obstructive airway disease participants (asthma, chronic obstructive pulmonary disease ... subtype categorised ...

Navega Therapeutics, a biotechnology company developing epigenetic gene therapies, today announced the receipt of a $4M Translational Science grant from CIRM for the relief of neuropathic pain.

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. My name is Tawanda, and I will be your ...

Apogee Therapeutics, Inc. (NASDAQ: APGE) has announced the dosing of the first patient in the part B portion of the phase 2 ...

A multi-institutional study led by researchers at Children's Hospital of Philadelphia (CHOP) is the first to identify one of ...

Areteia Therapeutics introduces dexpramipexole, a novel oral drug in Phase 3 trials for asthma and COPD, aiming for approval ...

HealthDay News — In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American Journal of Gastroenterology, recommendations are ...